Market research
ASZ1.F Alimera Sciences, Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 271M
- P/E ratio
- 5.03
- Analyst target
- 14.83
- Dividend yield
- Not available
- Beta
- 1.25
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- US0162592028
- Market cap
- 271M
- P/E ratio
- 5.03
- Analyst target
- 14.83
- Dividend yield
- Not available
- Beta
- 1.25
About
About Alimera Sciences, Inc
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia. As of September 16, 2024, Alimera Sciences, Inc. operates as a subsidiary of ANI Pharmaceuticals, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ASZ1.F discussion.
5 years, 5 months ago
Alimera Sciences, Inc is currently in a long term uptrend where the price is trading 21.9% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
Alimera Sciences, Inc's total revenue sank by 20.6% to $14M since the same quarter in the previous year.
Its net income has dropped by 296.2% to $-977K since the same quarter in the previous year.
Finally, its free cash flow fell by 187.4% to $-348K since the same quarter in the previous year.
Based on the above factors, Alimera Sciences, Inc gets an overall score of 2/5.